These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26693052)

  • 1. Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.
    Kawahara T; Ide H; Kashiwagi E; Patterson JD; Inoue S; Shareef HK; Aljarah AK; Zheng Y; Baras AS; Miyamoto H
    Am J Cancer Res; 2015; 5(10):2959-68. PubMed ID: 26693052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.
    Kawahara T; Aljarah AK; Shareef HK; Inoue S; Ide H; Patterson JD; Kashiwagi E; Han B; Li Y; Zheng Y; Miyamoto H
    Prostate; 2016 Jun; 76(8):744-56. PubMed ID: 26864615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ELK1 promotes urothelial tumorigenesis in the presence of an activated androgen receptor.
    Inoue S; Ide H; Mizushima T; Jiang G; Kawahara T; Miyamoto H
    Am J Cancer Res; 2018; 8(11):2325-2336. PubMed ID: 30555747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of α
    Nagata Y; Kawahara T; Goto T; Inoue S; Teramoto Y; Jiang G; Fujimoto N; Miyamoto H
    Am J Cancer Res; 2020; 10(12):4386-4398. PubMed ID: 33415006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.
    Kawahara T; Shareef HK; Aljarah AK; Ide H; Li Y; Kashiwagi E; Netto GJ; Zheng Y; Miyamoto H
    Oncotarget; 2015 Oct; 6(30):29860-76. PubMed ID: 26342199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer.
    Jiang G; Teramoto Y; Goto T; Mizushima T; Inoue S; Ide H; Nagata Y; Kashiwagi E; Baras AS; Netto GJ; Yang Z; Miyamoto H
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33652650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
    Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
    Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
    Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
    Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle.
    Hennenberg M; Strittmatter F; Beckmann C; Rutz B; Füllhase C; Waidelich R; Montorsi F; Hedlund P; Andersson KE; Stief CG; Gratzke C
    PLoS One; 2012; 7(11):e50904. PubMed ID: 23226423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer.
    Elahi Najafi MA; Yasui M; Teramoto Y; Tatenuma T; Jiang G; Miyamoto H
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen Receptor Signaling Induces Cisplatin Resistance via Down-Regulating GULP1 Expression in Bladder Cancer.
    Teramoto Y; Jiang G; Goto T; Mizushima T; Nagata Y; Netto GJ; Miyamoto H
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
    Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
    J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzalutamide inhibits proliferation of gemcitabine-resistant bladder cancer cells with increased androgen receptor expression.
    Kameyama K; Horie K; Mizutani K; Kato T; Fujita Y; Kawakami K; Kojima T; Miyazaki T; Deguchi T; Ito M
    Int J Oncol; 2017 Jan; 50(1):75-84. PubMed ID: 27909718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Phospho-ELK1 and Its Prognostic Significance in Urothelial Carcinoma of the Upper Urinary Tract.
    Inoue S; Ide H; Fujita K; Mizushima T; Jiang G; Kawahara T; Yamaguchi S; Fushimi H; Nonomura N; Miyamoto H
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer.
    Goto T; Kashiwagi E; Jiang G; Nagata Y; Teramoto Y; Baras AS; Yamashita S; Ito A; Arai Y; Miyamoto H
    Am J Cancer Res; 2020; 10(8):2523-2534. PubMed ID: 32905529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth.
    Rosati R; Patki M; Chari V; Dakshnamurthy S; McFall T; Saxton J; Kidder BL; Shaw PE; Ratnam M
    J Biol Chem; 2016 Dec; 291(50):25983-25998. PubMed ID: 27793987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling.
    Inoue S; Ide H; Mizushima T; Jiang G; Netto GJ; Gotoh M; Miyamoto H
    Mol Cancer Ther; 2018 Jun; 17(6):1303-1314. PubMed ID: 29592878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor knockdown enhances prostate cancer chemosensitivity by down-regulating FEN1 through the ERK/ELK1 signalling pathway.
    Xie W; Li S; Guo H; Zhang J; Tu M; Wang R; Lin B; Wu Y; Wang X
    Cancer Med; 2023 Jul; 12(14):15317-15336. PubMed ID: 37326412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of silodosin, a selective α1A-adrenoceptor antagonist, on bladder blood flow and bladder function in a rat model of atherosclerosis induced chronic bladder ischemia without bladder outlet obstruction.
    Goi Y; Tomiyama Y; Nomiya M; Sagawa K; Aikawa K; Yamaguchi O
    J Urol; 2013 Sep; 190(3):1116-22. PubMed ID: 23545103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology.
    Villa L; Capogrosso P; Capitanio U; Martini A; Briganti A; Salonia A; Montorsi F
    Adv Ther; 2019 Jan; 36(1):1-18. PubMed ID: 30523608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.